Answers are grounded in this paper and cite their sources.
The trial design provided efficient evaluation of pediatric dosing, safety, and efficacy of single-agent and combination targeted therapy. Age-based and weight-based dosing of trametinib with or without dabrafenib achieved target concentrations with manageable safety and demonstrated clinical efficacy and tolerability in BRAF V600-mutant LGG.
No takes yet. Share an insight, caveat, or question.
Bouffet et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: